None listed
Conditions
Interventions
Drug : -Investigational product: Sermion® 10 mg (Nicergoline 10 mg)
-Number of participants: Total of 50 subjects
-Dosage and administration: Oral administration, three times daily, before meals
-Trea
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Patients aged 65 years or older ? Patients with chronic dizziness and balance impairment who have not been diagnosed with peripheral vestibular disorders
Exclusion criteria
Exclusion criteria: ? Patients diagnosed with peripheral vestibular disorders such as benign paroxysmal positional vertigo (BPPV), vestibular neuritis, or Ménière’s disease ? Patients diagnosed with central nervous system disorders (e.g., brain tumor) ? Patients currently taking medications for cognitive impairment, panic disorder, or depression (e.g., donepezil [Aricept]) ? Patients with contraindications to nicergoline (e.g., history of allergic reaction to nicergoline), myocardial infarction or heart failure, severe hypotension, stroke or cerebral hemorrhage, or inability to receive an appropriate dose due to impaired renal function ? Patients with a history of hyperuricemia or gout
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in questionnaire scores (subjective improvement) | — |
Secondary
| Measure | Time frame |
|---|---|
| changes in Sensory Organization Test results;Effect on liver function as assessed by ALT/AST and uric acid levels before and after treatment. | — |
Countries
Korea, Republic of
Contacts
Public ContactYe Seul Kim
Asan Medical Center
Outcome results
None listed